Benitec Biopharma Q3 net loss narrows as expenses fall

Benitec Biopharma Inc

Benitec Biopharma Inc

BNTC

0.00


Overview

  • US gene therapy firm's fiscal Q3 net loss narrowed from prior year as expenses fell

  • R&D and G&A expenses declined yr/yr as BB-301 clinical development advanced


Result Drivers

  • The Company incurred $6.3 million of research and development expenses which was in line with $6.5 million for the comparable quarter ended March 31, 2025.


Company press release: ID:nGNX4vzvpx


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 EPS

-$0.24

Q3 Net Income

-$11.90 mln

Q3 Operating Income

-$13.60 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Benitec Biopharma Inc is $27.00, about 131.8% above its May 13 closing price of $11.65


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.